ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1253

Identification and Validation of Novel Putative Salivary Proteomic Biomarkers in Sjögren’s Syndrome and Different Disease Subsets

Chiara Baldini1, Daniela Martini1, Nadia Ucciferri2, Silvia Rocchiccioli2, Letizia Mattii3, Antonietta Raffaella Maria Sabbatini3, Francesca Sernissi1, Francesco Ferro1, Nicoletta Luciano1, Leonardo Lorenzini1, Marta Mosca4, Stefano Bombardieri1 and Antonella Cecchettini3, 1Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, 2Institute of Clinical Physiology, Pisa, Italy, Pisa, Italy, 3Department of Clinical and Experimental Medicine, University of Pisa, Italy, Pisa, Italy, 4University of Pisa, Pisa, Italy

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: biomarkers and proteomics, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Session Title: Genetics, Genomics and Proteomics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Salivary proteomics has recently appeared as a promising tool for the identification of novel diagnostic biomarkers for primary Sjögren’s syndrome (SS). However, to date the vast majority of the studies have focused the attention essentially on a restricted panel of high-abundance proteins, partially limiting the diagnostic potentiality of salivary proteomics. Moreover, the clinical inter-subject variability of SS seem to be reflected in the variability of the proteomic profiling. Aims of this study were: 1) to identify and validate putative salivary biomarkers in SS by using LC-MS/MS. 2) to highlight a specific fingerprint able to discriminate between different SS phenotypes, defined on the basis of the focus score (FS) and on the variation of the salivary flow rate (USFR).

Methods: USFR was collected from 18 patients with SS (AECG criteria, 2002). Six patients presented a high focus score (FS≥3) and normal USFR (group A), six patients presented a FS≥3 and an USFR<1.5 ml/15 (Group B),  and 6 patients a low focus score (FS<3) and USFR <1.5 ml/15 (group C). Six healthy volunteers (CTRL) represented the controls. ProteoPreop Immunoaffinity Albumin and IgG depletion kit (Sigma) was used for high-abundance proteins removal.  A high-throughput liquid chromatography tandem mass spectrometry (LC-MS/MS) was used for the proteomic analysis. Western Blotting (WB) and immunohistochemistry on minor salivary gland biopsies were used to validate proteomics results. Principal component analysis (PCA) was utilized for statistical analysis.

Results: Overall, 100 differentially expressed candidate biomarkers were identified. When compared to CTRL, the salivary proteomic profile of SS patients was characterized by 20 proteins which were significantly decreased and 113 proteins which were significantly increased. Among the differentially expressed proteins, of interest were: proline-rich proteins, cystatins, calcium-binding proteins, antigen binding proteins, profilin and other cell motion-related proteins, proteins involved in apoptosis, defence- and inflammatory-response. PCA distinctively discriminate between CTRL and SS patients stratified as previously described. Preliminary validation by WB and immunohistochemistry of prolactin-inducible protein precursor, cystatins C, S and SA, S-100A7 protein, kallikrein-6 and histhidine-rich glycoprotein indicated similar expression profile trends to those identified by LC-MS/MS. 

Conclusion: The proteomics workflow was able to detect novel candidate biomarkers potentially related to specific phenotypes of SS disease. These candidate biomarkers might be useful to improve SS non-invasive diagnosis and clinical stratification.


Disclosure: C. Baldini, None; D. Martini, None; N. Ucciferri, None; S. Rocchiccioli, None; L. Mattii, None; A. R. M. Sabbatini, None; F. Sernissi, None; F. Ferro, None; N. Luciano, None; L. Lorenzini, None; M. Mosca, None; S. Bombardieri, None; A. Cecchettini, None.

To cite this abstract in AMA style:

Baldini C, Martini D, Ucciferri N, Rocchiccioli S, Mattii L, Sabbatini ARM, Sernissi F, Ferro F, Luciano N, Lorenzini L, Mosca M, Bombardieri S, Cecchettini A. Identification and Validation of Novel Putative Salivary Proteomic Biomarkers in Sjögren’s Syndrome and Different Disease Subsets [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/identification-and-validation-of-novel-putative-salivary-proteomic-biomarkers-in-sjogrens-syndrome-and-different-disease-subsets/. Accessed June 29, 2022.
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-and-validation-of-novel-putative-salivary-proteomic-biomarkers-in-sjogrens-syndrome-and-different-disease-subsets/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies